Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

U.S. stock futures rose on Monday after Friday’s sharp fall as investors digested the tariff updates and earnings reports.

This article is a text version of a Wall Street Journal newsletter published earlier today.

S&P 500 E-Mini futures are up +0.46%, andMarch Nasdaq 100 E-Mini futures are up +0.61% this morning as investors shrugged off U.S. President Donald Trump’s latest tariff a ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Shutterstock Intel’s head of data-center and artificial-intelligence operations is leaving the group to take the helm of ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report), with ...

Vertex Pharmaceuticals (VRTX) stock is rising after receiving approval by the Food and Drug Administration (FDA) over its new non-opioid pain management drug, Journavx. Lastly, oil giants Exxon ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Wall Street also benefited from some dip-buying after clocking steep falls on Friday, as Trump flagged plans to impose tariffs on U.S. imports to match levies from U.S. trading partners on goods ...